Sandhya Shukla

About

Dr. Sandhya A. Shukla earned her Bachelor of Homeopathic Medicine and Surgery (BHMS) from Maharashtra University of Health Sciences (MUHS), Nashik, India. She also completed a Postgraduate Diploma in Emergency Medical Services (PGDEMS) and a Postgraduate Diploma in Hospital and Healthcare Management (PGDHHM) from Symbiosis International University, Pune, India. She obtained her Master of Science (MS) in Medical Pharmacology from Bharati Vidyapeeth Deemed University Medical College, Pune, India, and is currently pursuing a PhD in Medical Pharmacology. Dr. Shukla's research focuses on cancer therapeutics, with expertise in in vitro systems, in vivo models, and patient-derived xenograft (PDX) models. Her contributions to preclinical cancer, diabetes, and gynaecological research have resulted in several peer-reviewed publications, conference presentations, and academic lectures. She is an active member of professional scientific organizations and has received multiple academic awards and recognitions for her research contributions.

Employment

• Bharati Vidyapeeth Deemed University MS. Medical Pharmacology
  2022 - 2026
• INVENTRA MEDCLIN BIOMEDICAL HEALTHCARE AND RESEARCH CENTER (LLP) Chief Executive Officer (CEO) : (IMBHRC)
  2019 - Present

Education

• Bharati Vidyapeeth Deemed University Master of Science (MS) - Medical pharmacology
  2022 - 2026
• Symbiosis International University Post Graduate Diploma in Hospital and Healthcare Management (PGDHHM)
  2022 - 2023
• Symbiosis International University Post Graduate Diploma in Emergency Medical Services (PGDEMS)
  2019 - 2020
• Maharashtra University of Health Sciences Bachelor of Homeopathic Medicine and Surgery (BHMS)
  2009 - 2015

Projects & Funding

Projects & funding information is unavailable.

Publications (15)

• Farnesol as a Multifunctional Regulator of Fungal Biology: Mechanisms and Significance
  Applied Microbiology 2026 DOI: 10.3390/applmicrobiol6080098
  +Save
• Advancing Neurovascular Model Engineering with Integrated 3D Bioprinting and Microfluidic Chips for Study of Neurovascular and Neurodegenerative Disease Pathophysiology
  Bioprinting 2026 DOI: 10.1016/j.bprint.2026.e00497
  +Save
• Comparative study of Valsartan and Leucovorin alone or in combination for renal protection in methotrexate-induced acute kidney injury in rats
  Current Issues in Pharmacy and Medical Sciences 2026 DOI: 10.12923/cipms-2026-0009
  +Save
• Advances in Diagnosis and Management of Diabetes in Children and Adults with Focus on Drugs, Insulin, and Dietary Interventions
  2026 DOI: 10.20944/preprints202602.0253.v1
  +Save
• Integrated CRISPR-Cas9 and 3D Bioprinting Approach for Development and Evaluation of High-Throughput Advanced Organotypic Cancer Models
  2026 DOI: 10.20944/preprints202602.0262.v1
  +Save
• High-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy
  Current Oncology 2025 DOI: 10.3390/curroncol32120653
  +Save
• Integrating 3D Bioprinting with Organoid Technology-Based Breast Cancer Models for Drug Evaluation
  Organoids 2025 DOI: 10.3390/organoids4040026
  +Save
• High-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy
  2025 DOI: 10.20944/preprints202509.1577.v1
  +Save
• Molecular Insight and Antioxidative Therapeutic Potentials of Plant-Derived Compounds in Breast Cancer Treatment
  Onco 2025 DOI: 10.3390/onco5020027
  +Save
• Targeting Pathways and Mechanisms in Gynecological Cancer with Antioxidant and Anti-Inflammatory Phytochemical Drugs
  Onco 2025 DOI: 10.3390/onco5020024
  +Save